{
    "doi": "https://doi.org/10.1182/blood.V122.21.1661.1661",
    "article_title": "T-Cell Engineering For \u201coff-The-shelf\u201d Adoptive Immunotherapy ",
    "article_date": "November 15, 2013",
    "session_type": "801. Gene Therapy and Transfer: Poster I",
    "abstract_text": "Adoptive T-cell therapies, where exogenous expression of a chimeric antigen receptor (CAR) confers cancer recognition, have shown significant promise in initial clinical trials. However, present adoptive immunotherapy Methods are limited by the need for manipulation of autologous patient T-cells. To permit such an approach in an allogeneic context, Transcription Activator-Like Effector Nucleases (TALEN TM ) have been used to simultaneously inactivate the endogenous T cell receptor and CD52, a cellular target for a lymphodepleting treatment. This approach reduces the risk of GVHD while permitting proliferation and activity of the introduced T lymphocytes in the presence of the immunosuppressive drug alemtuzumab. Electroporation of primary T cells with mRNA coding for the appropriate TALEN TM result in double knock-out (dKO) frequencies of up to 70%. Furthermore, functional characterization demonstrates that the dKO cells are resistant to complement dependent lysis or in vivo depletion by alemtuzumab, and show no apparent potential for TCR-mediated activation. Finally, endowing the dKO cells with a CD19 CAR supports their capacity to kill CD19+ tumor targets as efficiently as unedited T-cells both in vitro and in vivo . Disclosures: Poirot: CELLECTIS THERAPEUTICS: Employment. Schiffer-Mannioui: CELLECTIS THERAPEUTICS: Employment. Philip: UCL Cancer Institute, London, United Kingdom: Employment. Derniame: CELLECTIS THERAPEUTICS: Employment. Gouble: CELLECTIS THERAPEUTICS: Employment. Chion-Sotinel: CELLECTIS THERAPEUTICS: Employment. Le Clerre: CELLECTIS THERAPEUTICS: Employment. Lemaire: CELLECTIS THERAPEUTICS: Employment. Grosse: CELLECTIS THERAPEUTICS: Employment. Cheung: UCL Cancer Institute, London, United Kingdom: Employment. Arnould: CELLECTIS THERAPEUTICS: Employment. Smith: CELLECTIS THERAPEUTICS: Employment. Pule: UCL Cancer Institute, London, United Kingdom: Employment. Scharenberg: CELLECTIS THERAPEUTICS: Employment.",
    "topics": [
        "alemtuzumab",
        "cancer",
        "cd19 antigens",
        "chimeric antigen receptors",
        "complement system proteins",
        "electroporation",
        "engineering",
        "graft-versus-host disease",
        "immunosuppressive agents",
        "immunotherapy, adoptive"
    ],
    "author_names": [
        "Laurent Poirot, PhD",
        "C\u00e9cile Schiffer-Mannioui, PhD",
        "Brian Philip",
        "Sophie Derniame, PhD",
        "Agnes Gouble, PhD",
        "Isabelle Chion-Sotinel, PhD",
        "Diane Le Clerre",
        "Laetitia Lemaire",
        "St\u00e9phanie Grosse, PhD",
        "Gordon Cheung",
        "Sylvain Arnould, PhD",
        "Julianne Smith, PhD",
        "Martin Pule, MD",
        "Andrew Scharenberg, PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Laurent Poirot, PhD",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "C\u00e9cile Schiffer-Mannioui, PhD",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Brian Philip",
            "author_affiliations": [
                "UCL Cancer Institute, London, London, United Kingdom, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sophie Derniame, PhD",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Agnes Gouble, PhD",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Isabelle Chion-Sotinel, PhD",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Diane Le Clerre",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Laetitia Lemaire",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "St\u00e9phanie Grosse, PhD",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gordon Cheung",
            "author_affiliations": [
                "UCL Cancer Institute, London, London, United Kingdom, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sylvain Arnould, PhD",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Julianne Smith, PhD",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Martin Pule, MD",
            "author_affiliations": [
                "Cellectis Therapeutics, London, United Kingdom"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrew Scharenberg, PhD",
            "author_affiliations": [
                "Cellectis Therapeutics, Paris, France, "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-25T06:44:38",
    "is_scraped": "1"
}